Stockhead
 
Biocurious: After a soft Roxus launch, LTR Pharma goes hard in US market

Biocurious: After a soft Roxus launch, LTR Pharma goes hard in US market

Having sold the first US commercial prescription for its spray-based erectile dysfunction drug Roxus, LTR Pharma eyes full FDA approval. 

 
Rise and Shine: Everything you need to know before the ASX opens

Rise and Shine: Everything you need to know before the ASX opens

Good morning! Here’s everything you need to know before the ASX flings open its doors and begins trading today.

 
 
The West faces a fluorspar problem and ASX explorers could hold the key

The West faces a fluorspar problem and ASX explorers could hold the key

Fluorspar plays a key role in steelmaking, clean energy and semiconductors, putting ASX explorers in focus as the West seeks new supply.

 
Tartana’s new boss says the critical minerals junior is ready to tell its story

Tartana’s new boss says the critical minerals junior is ready to tell its story

Tartana Minerals has a host of critical minerals options in Queensland, starting with a silver prospect untouched for almost two decades.

 
GCM’s graphite tech delivers strong test results, but the bigger prize awaits

GCM’s graphite tech delivers strong test results, but the bigger prize awaits

GCM has launched its graphite cooling products and made its first sales, with bigger orders now in its sights.

 
ASX healthcare stocks advance new approaches to prostate cancer